All News
Filter News
Found 808,606 articles
-
Revolutionary GAINSWave® Treatment for Erectile Dysfunction Offered by Center for Men's Health in California
1/29/2019
Center for Men's Health is making waves in the medical world of sexual wellness by joining the GAINSWave® movement to offer GAINSWave treatment!
-
Spero Health Names New Indiana Medical Director and Opens First Clinic in Indianapolis
1/29/2019
Spero Health, Inc., an integrated healthcare services organization specializing in local and affordable outpatient care for individuals suffering from substance use disorder, is pleased to announce the appointment of Dr. Darrin Mangiacarne as its new Central Indiana Medical Director.
-
Lung-MAP Precision Medicine Trial Expands To Include More Patients
1/29/2019
The Lung Cancer Master Protocol (Lung-MAP), the first precision medicine trial in lung cancer supported by the National Cancer Institute (NCI), part of the National Institutes of Health, is undergoing a major expansion to include patients with all non-small cell lung cancers – which make up about 85 percent of all lung cancer diagnoses in the U.S.
-
Neptune to Hold Conference Call to Discuss Third Quarter Results for the Three Months Period Ended December 31, 2018
1/29/2019
Neptune Wellness Solutions Inc. announces that it will be holding a conference call on February 13, 2019 at 5:00 PM (EST) to discuss its third quarter results for the three months period ended December 31, 2018.
-
McKesson Joins World Cancer Day Efforts
1/29/2019
Company Using Technology and Resources to Advance Cancer Care, Connecting Patients to Latest Therapies and Clinical Trials and Investing in Ways to Predict Cancer Earlier
-
Takeda’s Dengue Vaccine Candidate Meets Primary Endpoint in Pivotal Phase 3 Efficacy Trial
1/29/2019
Takeda’s dengue vaccine candidate was efficacious in preventing dengue fever in children and adolescents living in dengue-endemic countries in the ongoing Phase 3 trial
-
ANSYS 2019 R1 Delivers Speed and Ease of Use for Engineers Solving Next-Generation Product Challenges
1/29/2019
ANSYS Pervasive Engineering Simulation solutions empower companies across industries to retain engineers
-
Certara Launches Version 18 of its Physiologically-based Pharmacokinetic (PBPK) Simcyp Simulator
1/29/2019
New features designed to support the delivery of safer, more effective medications include advanced food staggering and tumor models for optimizing trial design and dose selection
-
HSBlox's Blockchain Technology Advances Clinical Trial Sample Management with Increased Visibility, Transparency and Tracking
1/29/2019
Digital Sample Manager utilizes distributed ledger technology to ensure sample tracking and real-time status updates
-
FACIT and Triphase Accelerator Announce New Partnership with Celgene for First-in-Class WDR5 Leukemia Therapy
1/29/2019
Largest transaction to date for Canadian-discovered preclinical asset arises from Ontario collaborators
-
MediPines Announces FDA Clearance of Breakthrough Respiratory Device, the MediPines Gas Exchange Monitor
1/29/2019
MediPines Corporation announced today it has received FDA 510(k) market clearance on its new non-invasive medical device, the MediPines Gas Exchange Monitor.
-
Alternate Health Announces Private Placement
1/29/2019
Alternate Health Corp., ("Alternate Health" or the "Company") (CSE:AHG) (OTCQB:AHGIF), wishes to announce that it is undertaking a non-brokered private placement (the "Private Placement") of unsecured convertible notes (the "Notes") under prospectus exemptions available under applicable securities legislation in the aggregate principal amount of up to CAD$12,000,000
-
Trovagene and PoC Capital Enter Agreement to Fund Clinical Development of Onvansertib in Metastatic Colorectal Cancer (mCRC)
1/29/2019
Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, developing drugs that target cell division (mitosis) for the treatment of leukemias, lymphomas and solid tumor cancers, today announced an agreement with PoC Capital, LLC, to fund clinical development of Onvansertib,
-
Invitae to announce fourth quarter and year-end 2018 financial results on February 19, 2019
1/29/2019
Invitae Corporation today announced that it will report its fourth quarter and year-end 2018 financial results on Tuesday, February 19, 2019 and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent developments.
-
Neovasc Receives Approval to Proceed with Phase 2 of TIARA-II Study from Clinical Regulators in Germany and the UK
1/29/2019
Successfully completed all Phase 1 requirements of TIARA-II
-
Lights Out for Insomnia: New Kanabo Research Study Offers Encouraging Results
1/29/2019
This in vivo study, evaluated the efficacy of varying compositions of active ingredients in cannabis to induce sleep, in comparison to Diazepam, the active ingredient in Valium.
-
Lattice Biologics Ltd. Reports Year End 2018 Results
1/29/2019
Successfully relocated processing facility to Belgrade, Montana, resulting in reduced overhead and increased operational efficiencies.
-
Nuvelution Pharma Appoints Milena Kanova-Petrova, M.D., as Senior Vice President of Operations
1/29/2019
Nuvelution Pharma, Inc. announced the appointment of Milena Kanova-Petrova, M.D., as Senior Vice President of Operations effective immediately.
-
AudioCure Pharma’s AC102 receives EMA orphan drug designation for the treatment of sudden sensorineural hearing loss (SSNHL)
1/29/2019
The EMA’s Committee for Orphan Medicinal Products has granted orphan drug designation to AC102, concluding that AudioCure’s lead compound may be of significant benefit for patients suffering with the rare and chronically debilitating disease of sudden sensorineural hearing loss (SSNHL).
-
TechCare Entered Into Joint Venture Contract With China-Israel Biological Technology Co. Ltd.
1/29/2019
TechCare Corp. (OTCQB: TECR), a technology company with a revolutionary delivery platform that uses vapor technology for natural health, wellness and beauty treatments, today announced that on January 21, 2019, it entered into a joint venture contract with China-Israel Biological Technology Co. Ltd. ("CIB").